This three-part webinar series aims to address the drug discovery process of rapid acting antidepressants both pre-clinically and clinically. Taking ketamine as a first example and moving on to examine the rapidly expanding field of psychedelic research, issues around translatability with ketamine as a reference point to compare similarities and differences. Finally, we will look to the future and where things are likely to be in the coming years.